2025
PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous-cell cancer treated with chemotherapy alone
Sachdeva M, Zhao J, Zhu K, Yap D, Wong N, Kumarakulasinghe N, Tey J, Sundar R. PD-L1 expression as a negative predictive biomarker in advanced esophageal squamous-cell cancer treated with chemotherapy alone. ESMO Gastrointestinal Oncology 2025, 7: 100109. DOI: 10.1016/j.esmogo.2024.100109.Peer-Reviewed Original ResearchAdvanced esophageal squamous-cell carcinomaPD-L1 expressionProgression-free survivalFirst-line chemotherapyPD-L1Overall survivalPredictive biomarkersKaplan-MeierKaplan-Meier (KM)Estimate time-to-event outcomesPatients treated with first-line chemotherapyNegative predictor of OSPhase III randomized trialRisk of tumor progressionProgression-free survival analysisPatients treated with chemotherapyCancer treated with chemotherapyNegative predictive biomarkerNon-significant increased riskPD-L1 subgroupsPositive predictive biomarkerEsophageal squamous-cell carcinomaPredictors of OSIndividual Patient Data Meta-AnalysisResponse to immunotherapy
2020
Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy
Cheng H, Lopez V, Lam S, Leung A, Li Y, Wong K, Au J, Sundar R, Chan A, De Ng T, Suen L, Chan C, Yorke J, Molassiotis A. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. Health And Quality Of Life Outcomes 2020, 18: 246. PMID: 32703223, PMCID: PMC7376939, DOI: 10.1186/s12955-020-01493-y.Peer-Reviewed Original ResearchConceptsFunctional Assessment of Cancer Therapy/Gynecologic Oncology Group-NeurotoxicityFACT/GOG-Ntx subscalePatients treated with chemotherapyCancer patients treated with chemotherapyFACT/GOG-NtxAssessment pointsFunctional assessmentNational Cancer Institute Common Terminology CriteriaInternal consistency reliabilityPeripheral Neuropathy ScaleEORTC QLQ-CIPN20Longitudinal studyEuropean Organization for ResearchResultsCronbach’s alpha coefficientCommon Terminology CriteriaLight touch testMotor itemsLow-to-moderateConsistency reliabilityAlpha coefficientEvaluate CIPNQLQ-CIPN20Four-factor structurePsychometric analysisMonofilament test
2016
Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement
Galsky M, Stensland K, Sfakianos J, Mehrazin R, Diefenbach M, Mohamed N, Tsao C, Boffetta P, Wiklund P, Oh W, Mazumdar M, Ferket B. Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. Journal Of Clinical Oncology 2016, 34: 2627-2635. PMID: 27269939, PMCID: PMC5012691, DOI: 10.1200/jco.2016.67.5033.Peer-Reviewed Original ResearchConceptsCombined-modality therapyLymph node involvementTreated with chemotherapyOverall survivalAdjuvant chemotherapyBladder cancerPreoperative chemotherapyNode involvementDistant metastasisChemotherapy trialsClinical evidence of regional lymph node involvementSurvival of patients treated with chemotherapyTreatment strategiesClinical lymph node involvementEvidence of regional lymph node involvementRegional lymph node involvementNational Cancer Data BasePatients treated with chemotherapyFirst-line chemotherapy trialsNeoadjuvant chemotherapy trialsTreated with cystectomyEffectiveness of treatment strategiesBladder cancer patientsLong-term survivalCystectomy
2007
Distinct Prognostic Role of Prostate-Specific Antigen Doubling Time and Velocity at Emergence of Androgen Independence in Patients Treated with Chemotherapy
Daskivich T, Regan M, Oh W. Distinct Prognostic Role of Prostate-Specific Antigen Doubling Time and Velocity at Emergence of Androgen Independence in Patients Treated with Chemotherapy. Urology 2007, 70: 527-531. PMID: 17905110, DOI: 10.1016/j.urology.2007.04.035.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAndrogen AntagonistsAndrogensAntineoplastic Agents, HormonalAntineoplastic Agents, PhytogenicDocetaxelDrug Resistance, NeoplasmHumansMaleMiddle AgedNeoplasms, Hormone-DependentPaclitaxelPrognosisProportional Hazards ModelsProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesSalvage TherapySurvival AnalysisTaxoidsTime FactorsConceptsProstate-specific antigen doubling timeAndrogen-independent prostate cancerEmergence of androgen-independent prostate cancerPatients treated with chemotherapyPSA nadirPSA valuesOverall survivalPrognostic informationShort prostate-specific antigen doubling timeEmergence of androgen independenceInstitutional prostate cancer databasePredictors of decreased OSAssociated with decreased OSAndrogen deprivation therapyCox proportional hazards regression modelsProstate cancer databaseType of chemotherapyProportional hazards regression modelsHazards regression modelsDoubling timeDeprivation therapyAndrogen independenceIntermediate prognosisProstate-specificPrognostic role
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply